[Flowcytometric-immunophenotyping for leukemia needs to be standardized]

Shan-Shan Chen1

  • 1Institute of Hematology, The People's Hospital, Peking University, Beijing 100044, China. chenss@public.bta.net.cn

Insights

Flowcytometric immunophenotyping (FCM-IM) aids in diagnosing hematological malignancies like leukemias and lymphoid proliferative disorders. Accurate interpretation requires multi-color analysis, CD45/SSC gating for pure cell populations, and cautious diagnosis of hybrid leukemia.

Area of Science:

  • Hematology
  • Immunology
  • Clinical Pathology

Context:

  • Flow cytometry is widely used in hospitals for routine tests.
  • Immunophenotyping by flow cytometry is crucial for diagnosing hematological malignancies.
  • Accurate diagnosis of leukemias and lymphoid proliferative disorders (LPDs) relies on FCM-IM.

Purpose:

  • To highlight the indispensable role of flowcytometric immunophenotyping (FCM-IM) in diagnosing hematological malignancies.
  • To outline critical parameters for accurate FCM-IM interpretation and standardization.
  • To emphasize the need for multi-parameter analysis and proper cell population gating.

Summary:

  • FCM-IM facilitates accurate diagnosis of leukemias and LPDs, providing therapeutically relevant information.
  • Key diagnostic considerations include direct multi-color staining, CD45/SSC gating for blast population isolation, and clear phenotype description.
  • Caution is advised for hybrid leukemia diagnoses based solely on FCM, considering antigen variability and lineage infidelity.

Impact:

  • Standardized FCM-IM protocols improve diagnostic accuracy and inter-laboratory consistency.
  • Proper application of FCM-IM enhances the diagnosis and management of hematological cancers.
  • This technique provides critical data for clinical decision-making in hematologic oncology.